Isis Pharmaceuticals price target raised to $43 from $31 at BMO Capital

theflyonthewall.com

BMO Capital increased its price target on Isis after the company reported data that indicated that its ISIS-APOC3-Rx drug lowered triglyceride levels in patients with familial chylomicronemia syndrome. The firm thinks the data shows the drug addresses a significant unmet need and could help it reach the market more quickly. It keeps an Outperform rating on the stock.

View Comments